SUMO1 Protein - Small Ubiquitin-Like Modifier 1

SUMO1 Protein - Small Ubiquitin-Like Modifier 1

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">SUMO1 Protein — Small Ubiquitin-Like Modifier 1</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Small ubiquitin-like modifier 1</td>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/genes/sumo1">SUMO1</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P63165" target="_blank">P63165</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>11.6 kDa</td>
</tr>
<tr>
<td class="label">Length</td>
<td>101 amino acids</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus, Cytoplasm</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>SUMO family, Ubiquitin-like proteins</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">25 edges</a></td>
</tr>
</table>

SUMO1 Protein — Small Ubiquitin-Like Modifier 1

Introduction

Sumo1 Protein Small Ubiquitin Like Modifier 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

SUMO1 Protein - Small Ubiquitin-Like Modifier 1

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">SUMO1 Protein — Small Ubiquitin-Like Modifier 1</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Small ubiquitin-like modifier 1</td>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/genes/sumo1">SUMO1</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P63165" target="_blank">P63165</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>11.6 kDa</td>
</tr>
<tr>
<td class="label">Length</td>
<td>101 amino acids</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus, Cytoplasm</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>SUMO family, Ubiquitin-like proteins</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">25 edges</a></td>
</tr>
</table>

SUMO1 Protein — Small Ubiquitin-Like Modifier 1

Introduction

Sumo1 Protein Small Ubiquitin Like Modifier 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

SUMO1 (Small Ubiquitin-like Modifier 1) is a member of the SUMO family of ubiquitin-like proteins, encoded by the [SUMO1 gene](/genes/sumo1). It plays crucial roles in post-translational modification through SUMOylation, regulating protein function, localization, stability, and interactions.[@hay2005]

Structure

SUMO1 is a small protein (~101 amino acids) with a ubiquitin-like fold:

• N-terminal flexible region
• Ubiquitin-like core domain
• C-terminal glycine residue for conjugation

Sequence

The C-terminal region contains the motif required for conjugation:

• Gly-Gly motif essential for isopeptide bond formation

Normal Function

SUMOylation Pathway

Activation: SUMO is activated by E1 (SAE1/UBA2)

Conjugation: Transferred to E2 (UBC9)

Ligation: E3 ligases facilitate substrate modification

Target Proteins

SUMO1 modifies thousands of proteins involved in:

• Transcription regulation
• DNA repair
• Signal transduction
• Nuclear transport
• Protein degradation

Role in Disease

Neurodegenerative Diseases

SUMOylation of disease-related proteins:

• [Alpha-synuclein](/proteins/alpha-synuclein) (PD): SUMOylation affects aggregation
• [Tau](/proteins/tau) (AD): SUMOylation influences phosphorylation
• [Huntingtin](/proteins/huntingtin) (HD): SUMOylation modulates toxicity
• [TDP-43](/proteins/tdp-43) (ALS): SUMOylation affects localization

Other Diseases

• Cancer: Altered SUMOylation of oncogenes
• Diabetes: SUMOylation of insulin signaling proteins

Key Publications

[SUMO: a history of modification](https://doi.org/10.1016/j.molcel.2005.09.013). Molecular Cell, 2005.

[SUMOylation in neurodegenerative disease](https://doi.org/10.1016/j.tins.2013.08.003). Trends in Neurosciences, 2013.

External Links

• UniProt: [https://www.uniprot.org/uniprot/P63165](https://www.uniprot.org/uniprot/P63165)

See Also

• [SUMO1 Gene](/genes/sumo1)
• [SUMOylation](/mechanisms/sumoylation)
• [Proteins Index](/proteins)

Background

The study of Sumo1 Protein Small Ubiquitin Like Modifier 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

SUMO1 in Alzheimer's Disease

Amyloid Metabolism

SUMO1 plays a role in [amyloid precursor protein](/entities/app-protein) (APP) processing:

• SUMOylation of BACE1 affects [beta-secretase](/entities/bace1) activity
• SUMOylated APP may reduce [amyloid-beta](/proteins/amyloid-beta) production
• Competition between SUMOylation and ubiquitination influences APP trafficking

Tau Pathology

SUMO1-mediated modifications affect tau protein:

• SUMOylation at lysine residues can protect tau from degradation
• Hyper-SUMOylation associated with tau aggregation in AD brain
• SUMO-specific proteases (SENPs) are dysregulated in AD

Neuroinflammation

SUMOylation modulates inflammatory responses:

• [NF-κB](/entities/nf-kb) SUMOylation negatively regulates inflammation
• SENP1 overexpression reduces neuroinflammation in models
• SUMO1 levels correlate with microglial activation markers

SUMO1 in Parkinson's Disease

Alpha-Synuclein Modifications

SUMO1 modifies alpha-synuclein (α-syn):

• SUMOylation reduces α-syn aggregation
• SUMO-deficient mutants show increased toxicity
• Parkin is a SUMO E3 ligase, linking PD genetics to SUMOylation

Mitochondrial Quality Control

SUMO1 is involved in mitochondrial dynamics:

• Mitofusin 2 SUMOylation regulates mitochondrial fusion
• PINK1/Parkin mitophagy pathway involves SUMOylation
• SUMO1 protects against mitochondrial toxins

LRRK2 Regulation

LRRK2, a major PD gene product:

• LRRK2 undergoes SUMOylation
• SUMOylation affects LRRK2 kinase activity
• G2019S mutation alters SUMOylation patterns

SUMO1 in Other Neurodegenerative Diseases

Huntington's Disease

• Huntingtin protein is SUMOylated
• SUMOylation promotes aggregation
• SUMOylation may enhance transcriptional dysfunction

Amyotrophic Lateral Sclerosis (ALS)

• [TDP-43](/mechanisms/tdp-43-proteinopathy) SUMOylation affects aggregation
• FUS protein modifications alter nuclear import
• SOD1 SUMOylation influences mutant toxicity

Therapeutic Implications

Small Molecule Inhibitors

SUMOylation pathway inhibitors in development:

• Ginkgolic acid (SAE inhibitor)
• 2-D08 (Ubc9 inhibitor)
• Spectomycin B1 (SENP inhibitor)

Gene Therapy Approaches

• SUMO1 overexpression strategies
• SENP modulation
• SUMO-specific protease activation

Repurposed Drugs

Existing drugs with SUMO modulatory effects:

• Anthrax lethal toxin (SENP1 inhibitor)
• Auranofin (thioredoxin reductase inhibitor affects SUMOylation)

Research Methods

Detection Techniques

• Anti-SUMO1 antibodies for immunoblotting
• SUMOylation site mapping via mass spectrometry
• SUMO-conjugating enzyme assays

Model Systems

• Cell cultures: HEK293, SH-SY5Y, primary [neurons](/entities/neurons)
• Animal models: Mouse, Drosophila, C. elegans
• iPSC-derived neurons from neurodegenerative disease patients

Summary

SUMO1 plays complex roles in neurodegeneration through post-translational modification of disease-related proteins. Both protective and pathogenic effects have been described depending on the specific substrate and cellular context. Understanding the balance between SUMOylation and ubiquitination provides insights into disease mechanisms and therapeutic targeting.

References

Hay RT et al., SUMO: a history of modification, Molecular Cell, 2005 (2005)

Unknown, SUMOylation in neurodegenerative disease (2013)